Observational studyJournal of the American Heart Association2026
Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation.
Observational study in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReal-world research has identified differences in effectiveness and safety between direct oral anticoagulants (DOACs) when used to reduce risks of stroke and systemic embolism in patients with atrial fibrillation. However, treatment decisions and subsequent outcomes are poorly understood in patients with atrial fibrillation who experience bleeding when receiving a DOAC.
methodsA retrospective observational study was conducted using US claims data from Optum's Clinformatics Data Mart Database (January 2012 through March 2024). The study population comprised adults with nonvalvular atrial fibrillation who initiated a DOAC and had a subsequent claim for bleeding. After propensity score matching, patients who persisted with the same DOAC after bleeding were compared with those who switched to another DOAC. The main outcomes were major bleeding and stroke/systemic embolism.
resultsAmong 59 620 apixaban initiators and 21 004 rivaroxaban initiators with bleeding while on therapy, 408 apixaban-to-rivaroxaban switchers were matched with 2040 persistent apixaban users, and 901 rivaroxaban-to-apixaban switchers were matched with 4505 persistent rivaroxaban users. Compared with persisting with apixaban following a bleeding event, apixaban-to-rivaroxaban switching was associated with a higher risk of major bleeding (hazard ratio [HR], 1.690 [95% CI, 1.130-2.527]) and a similar risk of stroke/systemic embolism (HR, 1.793 [95% CI, 0.765-4.202]). Compared with persisting with rivaroxaban, rivaroxaban-to-apixaban switching was associated with a lower risk of major bleeding (HR, 0.651 [95% CI, 0.460-0.920]) and a similar risk of stroke/systemic embolism (HR, 0.783 [95% CI, 0.371-1.652]).
conclusionsThese findings suggest that the choice of DOAC after a bleeding event can affect treatment outcomes in patients with atrial fibrillation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.